EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC

Fengwu Lin, Miaoqing Zhao, Qiang Wu, Wenqi Wu, Xiaoying Wu, Ya Ma iD, Jiani C Yin, Meng Yang, Min Gao iD

Genes, Chromosomes and Cancer · 2025-11 · 64 (11)

DOI: 10.1002/gcc.70088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, online erschienen am 22.11.2025. Verfasst von Fengwu Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Afatinib, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, Wu Jieping Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Afatinib, an irreversible pan‐ERBB family inhibitor, has demonstrated promising efficacy in non‐small cell lung cancer (NSCLC) patients with uncommon EGFR activating mutations. However, besides the acquisition of the secondary T790M mutation, other resistance mechanisms to afatinib remain to be explored. Materials and Methods This study retrospectively included 37 NSCLC patients harboring either EGFR or ERBB2 activating mutations, who had received afatinib as first‐line treatment. Targeted next‐generation sequencing data on the baseline and post‐progression samples were subjected to analysis. Comparative analyses of clinical parameters and genomic features were performed.

Results

Overall, the progression‐free survival of the EGFR ‐mutated patients on first‐line afatinib was longer than that of the ERBB2 ‐positive patients (hazard ratio = 0.35 [95% confidence interval = 0.15–0.79], p = 0.008). Primary resistance was associated with the presence of exon 20 insertion mutation ( p = 0.011), higher tumor mutational burden ( p = 0.009), and higher proportion of APOBEC signature ( p = 0.012), which were all enriched in the ERBB2 ‐mutated cohort. We further characterized acquired resistance to afatinib and discovered that baseline EGFR exon 19 deletions and higher levels of chromosomal instability and age‐related mutational signatures would contribute to the development of known resistance mechanisms such as EGFR T790M or MET amplification. We also report gaining EGFR activating mutations and losing CDKN2A , NF1 , or the original ERBB2 mutations as novel resistance mechanisms to afatinib for ERBB2 ‐mutated patients.

Conclusion

The study identified multiple genomic characteristics associated with primary and secondary resistance to first‐line afatinib treatment in EGFR ‐ and ERBB2 ‐positive subpopulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AfatinibCarcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmProtein Kinase InhibitorsHumansFemaleMaleMiddle AgedErbB ReceptorsAgedRetrospective StudiesMutationErb-b2 Receptor Tyrosine KinasesAdultAged, 80 and overTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

EGFRERBB2afatinibclinical outcomeexon 20 insertionsresistance mechanisms

Substanzen

AfatinibErbB ReceptorsProtein Kinase InhibitorsErb-b2 Receptor Tyrosine KinasesTyrosine Kinase InhibitorsEGFR protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
  • Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Department of Clinical Biochemistry and Molecular Biology, The First Affiliated Hospital of Hainan Medical University, Haikou, China.
  • Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
  • National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of…
  • Department of Radiation Therapy, Shandong Cancer Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.

ORCID-Profile: Ya Ma, Min Gao

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • Wu Jieping Medical Foundation

Zitieren

APA

Lin, F., Zhao, M., Wu, Q., Wu, W., Wu, X., Ma, Y., Yin, J. C., Yang, M., & Gao, M. (2025). Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC. Genes, Chromosomes and Cancer, 64(11). https://doi.org/10.1002/gcc.70088

Vancouver

Lin F, Zhao M, Wu Q, Wu W, Wu X, Ma Y, et al. Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC. Genes, Chromosomes and Cancer. 2025;64(11). doi:10.1002/gcc.70088

BibTeX
@article{Lin2025,
  author = {Lin, Fengwu and Zhao, Miaoqing and Wu, Qiang and Wu, Wenqi and Wu, Xiaoying and Ma, Ya and Yin, Jiani C and Yang, Meng and Gao, Min},
  title = {Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC},
  journal = {Genes, Chromosomes and Cancer},
  year = {2025},
  volume = {64},
  number = {11},
  doi = {10.1002/gcc.70088}
}
Kostenlos starten →